Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Psychedelics Gain Momentum in Big Pharma

31 July 2026 · By · Wire by Fusion42

Published

31 July 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at labroots.com →

◆ Verified

Fusion42 · 1 August 2026 · Fusion42 review

Eli Lilly’s $2.8 billion acquisition of AtaiBeckley marks a significant commitment by Big Pharma to psychedelic therapies for depression and PTSD, supported by recent positive trial results and FDA guidance signalling regulatory approval pathways.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your mental health biotech startup just saw the regulator clear a path for psychedelic drug approvals. Now is the time to engage with the FDA and position your pipeline for this newly validated route to market.

◆ Coverage

1 source · 31 Jul 2026

◆ Related on Wire

◆ Topics

Biotechpsychedelicsbig-pharmadrug-developmentFDA-guidancemental-health